Skip to content

Study · Not a test of the peptide alone · 2017

5 results

Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial.

Rodbard HW, Bode BW, Harris SB, Rose L, Lehmann L, Jarlov H, Thurman J

Diabetic medicine : a journal of the British Diabetic Association7 Oct 2016Cited by 87 (Europe PMC)

PMID27589252 (opens in a new tab)PMCIDPMC5811787 (opens in a new tab)DOI10.1111/dme.13256 (opens in a new tab)PepBankPUB-27589252
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on sulphonylurea, the combination IDegLira lowered HbA1c more than placebo (estimated difference -11 mmol/mol).

    In plain wordsIn adults with type 2 diabetes, the combination product IDegLira lowered HbA1c more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change at week 26
    Study

    n = 435

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    HbA1c estimated treatment difference
    −11 mmol/mol
    IDegLira vs placebo

    Source sentences

    Summary
    The mean HbA1c decreased from 63 mmol/mol (7.9%) to 46 mmol/mol (6.4%) with IDegLira and to 57 mmol/mol (7.4%) with placebo [estimated treatment difference -11 mmol/mol (95% CI -13; -10) or -1.02% (95% CI -1.18; -0.87); P < 0.001].
    1 context sentence
    Summary · context
    In this 26-week, double-blind trial, adults with Type 2 diabetes [HbA1c 53-75 mmol/mol (7.0-9.0%)] were randomized to IDegLira (n = 289) or placebo (n = 146) as add-on to pre-trial sulphonylurea ± metformin, titrating to a fasting glycaemic target of 4.0-6.0 mmol/l.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on sulphonylurea, more participants reached the HbA1c target below 7% with IDegLira (79.2%) than with placebo (28.8%).

    In plain wordsIn adults with type 2 diabetes, more people reached the HbA1c target with the combination product IDegLira than with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseHbA1c target below 7% achieved
    Study

    n = 435

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    HbA1c target achieved
    79.2%
    IDegLira
    HbA1c target achieved
    28.8%
    placebo

    Source sentences

    Summary
    The HbA1c target of 53 mmol/mol (<7%) was achieved by 79.2% of participants in the IDegLira group vs 28.8% in the placebo group [estimated odds ratio 11.95 (95% CI 7.22; 19.77); P < 0.001].
    1 context sentence
    Summary · context
    In this 26-week, double-blind trial, adults with Type 2 diabetes [HbA1c 53-75 mmol/mol (7.0-9.0%)] were randomized to IDegLira (n = 289) or placebo (n = 146) as add-on to pre-trial sulphonylurea ± metformin, titrating to a fasting glycaemic target of 4.0-6.0 mmol/l.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes on sulphonylurea, body weight changed by +0.5 kg with IDegLira versus -1.0 kg with placebo (difference 1.48 kg).

    In plain wordsIn adults with type 2 diabetes, weight rose slightly with the combination product IDegLira while it fell slightly with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseBody weight change
    Study

    n = 435

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Mean weight change
    0.5 kg
    IDegLira
    Mean weight change
    −1 kg
    placebo

    Source sentences

    Summary
    Mean weight change was +0.5 kg with IDegLira vs -1.0 kg with placebo [estimated treatment difference 1.48 kg (95% CI 0.90; 2.06); P < 0.001].
    1 context sentence
    Summary · context
    In this 26-week, double-blind trial, adults with Type 2 diabetes [HbA1c 53-75 mmol/mol (7.0-9.0%)] were randomized to IDegLira (n = 289) or placebo (n = 146) as add-on to pre-trial sulphonylurea ± metformin, titrating to a fasting glycaemic target of 4.0-6.0 mmol/l.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 04HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome

    In adults with type 2 diabetes on sulphonylurea, confirmed hypoglycaemia was more frequent with IDegLira (41.7%) than with placebo (17.1%).

    In plain wordsIn adults with type 2 diabetes, low blood sugar was more common with the combination product IDegLira than with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseConfirmed hypoglycaemia
    Study

    n = 435

    Comparator
    Placebo
    Outcome group
    Adverse events · Metabolic and weight

    Measurements

    Confirmed hypoglycaemia
    41.7%
    IDegLira
    Confirmed hypoglycaemia
    17.1%
    placebo

    Source sentences

    Summary
    Confirmed hypoglycaemia occurred in 41.7 and 17.1% of IDegLira- and placebo-treated participants, respectively, with rates of 3.5 vs 1.4 events/patient-years of exposure [estimated rate ratio 3.74 (95% CI 2.28; 6.13); P < 0.001].
    1 context sentence
    Summary · context
    In this 26-week, double-blind trial, adults with Type 2 diabetes [HbA1c 53-75 mmol/mol (7.0-9.0%)] were randomized to IDegLira (n = 289) or placebo (n = 146) as add-on to pre-trial sulphonylurea ± metformin, titrating to a fasting glycaemic target of 4.0-6.0 mmol/l.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  5. 05HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome

    In adults with type 2 diabetes on sulphonylurea, serious adverse event rates were 20.3 per 100 patient-years with IDegLira and 8.0 with placebo.

    In plain wordsIn adults with type 2 diabetes, serious side effects were reported more often with the combination product IDegLira than with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseSerious adverse events
    Study

    n = 435

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body

    Measurements

    Serious adverse events per 100 patient-years
    20.3 per 100 patient-years
    IDegLira
    Serious adverse events per 100 patient-years
    8 per 100 patient-years
    placebo

    Source sentences

    Summary
    The rates of serious adverse events were 20.3 and 8.0 per 100 patient-years of exposure with IDegLira and placebo, respectively, without obvious patterns in the type of events.
    1 context sentence
    Summary · context
    In this 26-week, double-blind trial, adults with Type 2 diabetes [HbA1c 53-75 mmol/mol (7.0-9.0%)] were randomized to IDegLira (n = 289) or placebo (n = 146) as add-on to pre-trial sulphonylurea ± metformin, titrating to a fasting glycaemic target of 4.0-6.0 mmol/l.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01618162

The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy

Novo Nordisk A/Sn = 43529 Aug 2012 to 23 Oct 2013

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 27 Oct 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.